Phathom Pharmaceuticals (NASDAQ:PHAT) Receives Buy Rating from HC Wainwright
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $28.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 453.36% from the stock’s current price. PHAT has been […]
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $28.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 453.36% from the stock’s current price. PHAT has been […]
